Is this Biogen's Biggest Risk?

With peak sales of its blockbuster MS drug pegged at $3.8 billion, and two new drugs in the hemophilia market, what could derail this stock from liftoff this year?

Jul 1, 2014 at 5:00PM

Looking for a stock with excellent near-term revenue growth potential and a 25.1% net margin over the trailing-12 months (per S&P Capital IQ)? Look no further than big biotech Biogen (NASDAQ:BIIB).

What makes Biogen even more tempting right now is that it seems a little ignored. Biogen sold off hard in March -- as did the rest of the sector -- but it hasn't participated equally in sector's comeback. And that's despite the FDA's recent nod to Biogen's new hemophilia drug Eloctate (peak sales estimate of $1.5 billion), and the strong launch of Biogen's blockbuster MS drug Tecfidera.

We all know that the time to buy a stock is when it's flying under the radar, and with Biogen's Q1 sales surging 51% year-over-year to $2.1 billion, is this a stock to buy?

Biotech investing is a chancy business, so it's worth digging deep to find this stock's biggest risk. Once you do, you'll find a fascinating story -- and one fraught with danger.

Could history repeat itself?
As individuals, we are all products of our past to a certain degree, and the same could be said of companies. That's why front-and-center in Biogen's outlining of 10-Q risks were the executives' major concerns about Tecfidera's launch.

The filings warn, "If we are unable to successfully execute on our commercialization plans for TECFIDERA, our future revenue growth ...may be adversely affected." Specifically, the filings state, "damage to our sales and reputation, and physician and patient confidence in Tecfidera relating to any adverse experiences or events that may occur with patients treated with Tecfidera."

It's a mistake to think those sentences are just standard securities filing legal jargon.

Biogen's execs are well aware of what happened the last time the company did a major launch of another highly promising and novel MS drug. Despite high expectations for that drug, the company's following year was bedeviled with nightmarish problems.

Tysabri's rough launch
Tysabri -- touted by some as a miracle drug -- won FDA approval in November, 2004. Less than a year later, the drug was forced off the market after several patients died from a rare brain infection known as PML. Tysabri wasn't relaunched until 2006, after Biogen developed a test used to predict if a prospective candidate might be vulnerable to PML.

An experience like this not only changes the commercial trajectory of a drug company short-term, it can have serious long-term effects on the company's reputation with doctors and patients. Biogen has been down a very difficult trail with new MS drugs; that's why they are sweating the launch of Tecfidera.

Biogen's battle with Novartis and Sanofi
Biogen has another problem with Tecfidera. The drug doesn't have the market to itself.

Besides Tecfidera, the most effective MS oral treatments are Novartis' (NYSE:NVS) Gilenya and Sanofi's (NYSE:SNY) Aubagio. Gilenya was tied to PML, when the FDA sent out a safety alert in August last year.

Sanofi's drug was pegged by AdverseEvents for probable safety-related action from the FDA in January. As reported by FiercePharma, the AdverseEvents "RxScore" -- a scale that indicates safety, with 100 representing the highest risk the drug scaled at 48. It should be noted side effects are sometimes not caused by the drugs being reported, as patients often take multiple drugs.

In addition, AdverseEvents reported a few days ago that two other MS drugs, Pfizer's MS drug Rebif and Novartis's Extavia, were both associated with depression and suicidal behavior.

Meanwhile, how are Tecfidera patients faring?
According to Jeffery Cohen, a neurologist at the Cleveland Clinic, the drug has some problems. "At least right after initiation there's more side effects," Dr. Cohen said. He reported that perhaps as many as 10% or 20% of patients discontinued the medication because of side effects.

AdverseEvents also reported a few days ago that while Tecfidera had a higher association with gastrointestinal upset than did its rivals, the drug had comparatively few reported adverse events.

You can almost hear the executives at Biogen sigh in relief.

Tecfidera cannibalizing Tysabri
Not so fast, though. It turns out that Biogen also faces the risk of Tecfidera cannibalizing sales of other drugs -- like Tysabri, for example, which brought in almost half a billion in first quarter 2014.

Multiple Sclerosis is a disease affecting nearly 400,000 people in the United States and 2.5 million globally. Right now, Biogen looks like it has brought an excellent new oral medication to market, one that could easily join the list of 2014 superstars.

But the ramp up of a blockbuster-to-be is always highly risky, and that's never more true than when the disease is MS. Biogen's fate will be the tale of two drugs in 2014--Tysabri and Tecfidera. Biogen bought out the full rights to Tysabri last year, despite continuing problems with Tysabri's safety profile, so investors need to keep a watchful eye on both of them.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

 

Cheryl Swanson owns shares of Biogen Idec. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers